Cybin (NASDAQ:HELP) Stock Falls 7.7% – What’s Next?

Cybin Inc. (NASDAQ:HELP – Get Free Report) traded down 7.7% during mid-day trading on Tuesday. The company traded as low as $7.31 and last traded at $7.0820. Approximately 489,730 shares changed hands during trading, a decline of 63% from the average daily volume of 1,330,713 shares. The stock had previously closed at $7.67.

Analysts Set New Price Targets

HELP has been the subject of several research reports. Barclays began coverage on shares of Cybin in a research report on Friday, September 18th. They issued an “overweight” rating and a $35.00 target price for the company. TD Cowen raised their price target on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Wall Street Zen downgraded Cybin from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, Wells Fargo & Company lifted their price target on Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. Six equities research analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $47.33.

Read Our Latest Research Report on Cybin

Cybin Price Performance

The company has a 50 day simple moving average of $10.91 and a 200-day simple moving average of $7.81. The firm has a market cap of $549.89 million, a PE ratio of -2.27 and a beta of 0.64.

Cybin (NASDAQ:HELP – Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.74). On average, sell-side analysts predict that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling at Cybin

In other Cybin news, insider Eric H. L. So bought 100,000 shares of Cybin stock in a transaction that occurred on Tuesday, September 8th. The shares were bought at an average price of $12.39 per share, with a total value of $1,239,000.00. Following the acquisition, the insider owned 4,465,014 shares in the company, valued at approximately $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Greg Cavers bought 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 29th. The stock was acquired at an average price of $12.91 per share, for a total transaction of $38,730.00. Following the transaction, the chief financial officer owned 3,000 shares in the company, valued at $38,730. This trade represents a ? increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 688,000 shares of company stock worth $8,422,830 in the last quarter. 15.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. AXQ Capital LP purchased a new position in shares of Cybin in the second quarter worth about $75,000. Farther Finance Advisors LLC boosted its holdings in Cybin by 927.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company’s stock valued at $280,000 after acquiring an additional 20,597 shares during the period. State Street Corp purchased a new stake in Cybin during the 3rd quarter valued at about $363,000. Goldman Sachs Group Inc. purchased a new stake in Cybin during the 3rd quarter valued at about $568,000. Finally, WealthPlan Investment Management LLC bought a new position in Cybin during the 3rd quarter worth approximately $1,272,000. 17.94% of the stock is owned by institutional investors.

About Cybin

(Get Free Report)

Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.

Further Reading

Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.